SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months

New analyses from completed Phase 2 STRIVE trial support once-weekly, long-acting rezafungin for the treatment of candidemia and invasive candidiasis in high-risk patient populations SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc.

SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced an oral presentation and four poster

Invasive candidiasis (IC) is characterised as a severe, life-threatening Candida infection of the bloodstream and/or deep/visceral tissues 1,2 Despite advances in antifungal therapy, IC is still an area of significant unmet patient need associated with high mortality, particularly in

SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of

Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara’s antifungal and antiviral programs SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at